Journal: bioRxiv
Article Title: The Th1/Th17 axis regulates chimeric antigen receptor (CAR) T cell therapy toxicities
doi: 10.1101/2025.03.06.641668
Figure Lengend Snippet: A. Schematic representation of 51 IL2Rα-/- (KO) mice treated with 2M CAR-T followed by administration of either Isotype IgG or 12.5 mg/kg (i.p.) of anti-IL-6R mAb or anti-IFNγ mAb on a twice weekly basis. Data is pooled from 2 independantly performed experiments. B-J. Serum analysis in pre vs week 4 post CAR-T treated mice of cytokines IL-6 (B, E, H), TNFα (C, F, I) and IFNγ (D, G, J). Pre and post cytokines are paired values taken from each mouse alive at week 4 for each cohort (N=10 for CAR-T +Isotype, N=12 for CAR-T + anti-IL-6R mAb and N=10 for CAR-T + anti-IFNγ mAb). K-N. Comparison of IFNγ (K, L) and CXCL9 (M, N) between CAR-T treated KO mice with or without anti-IFNγ mAb. Pre and post cytokine values from K-N are paired values taken from KO mice that had samples for both pre and post cytokines at week 1 (N=7 for CAR-T Group and N=8 for CAR-T + anti-IFNγ mAb group). Data from K-N are from one experiment. O. The impact of CRS management in KO mice was determined by measuring Kaplan-Meier overall survival. Error bars represent SEM. P values *P < .05, **P < .01, and ***P < .001 were considered significant. P values for cytokine bar plots B-J and K-N were generated using paired t test. P values for Kaplan-Meier survival curve O was generated using Log-rank (Mantel-Cox) test.
Article Snippet: For CRS mitigation using blockade of IL-6R and IFNγ, KO and WT mice were treated intraperitoneally with either 12.5 mg/kg (250-300 μg/mouse) of murine anti-IL-6R mAb (MP5-20F3; BioXcell) or 250 μg/mouse of murine anti-IFNγ mAb (Clone XMG1.2, Bioxcell) or Isotype control (Rat IgG1, clone HRPN, BioXcell) (N=21 for ) as described [ , ].
Techniques: Comparison, Generated
